Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia

Eur J Clin Pharmacol. 2023 Jan;79(1):71-77. doi: 10.1007/s00228-022-03423-x. Epub 2022 Nov 15.

Abstract

Purpose: The aim of this study was to explore the time-course of hospitalization due to hyponatremia associated with omeprazole and esomeprazole.

Methods: In this register-based case-control study, we compared patients hospitalized with a main diagnosis of hyponatremia (n = 11,213) to matched controls (n = 44,801). We used multiple regression to investigate time-related associations between omeprazole and esomeprazole and hospitalization because of hyponatremia.

Results: The overall adjusted OR (aOR) between proton pump inhibitor (PPI) exposure, regardless of treatment duration and hospitalization with a main diagnosis of hyponatremia, was 1.23 (95% confidence interval CI 1.15-1.32). Exposure to PPIs was associated with a prompt increase in risk of hospitalization for hyponatremia from the first week (aOR 6.87; 95% CI 4.83-9.86). The risk then gradually declined, reaching an aOR of 1.64 (0.96-2.75) the fifth week. The aOR of ongoing PPI treatment was 1.10 (1.03-1.18).

Conclusion: The present study shows a marked association between omeprazole and esomeprazole and hyponatremia related to recently initiated treatment. Consequently, newly initiated PPIs should be considered a potential culprit in any patient suffering from hyponatremia. However, if the patient has had this treatment for a longer time, the PPI should be considered a less likely cause.

Keywords: Adverse effect; Esomeprazole; Hyponatremia; Omeprazole; PPI; SIADH.

MeSH terms

  • Case-Control Studies
  • Esomeprazole* / adverse effects
  • Hospitalization
  • Humans
  • Hyponatremia* / chemically induced
  • Hyponatremia* / epidemiology
  • Omeprazole / adverse effects
  • Proton Pump Inhibitors / adverse effects

Substances

  • Esomeprazole
  • Omeprazole
  • Proton Pump Inhibitors